Strategic Signals Weekly

Praxis Precision Medicines announced a three-month extension of the PDUFA target action date for its relutrigine NDA, moving it to December 27, 2026. The extension was due to the FDA deeming the company's submission of additional sensitivity analyses a "major amendment." Importantly, no new clinical studies were requested, and the FDA did not raise any safety or manufacturing concerns.

Drug: relutrigine · Indication: SCN2A and SCN8A developmental and epileptic encephalopathies (DEEs)

Jade Biosciences, Inc. entered into a worldwide, exclusive, royalty-bearing license agreement with Paragon Therapeutics, Inc. for monospecific antibodies targeting an undisclosed target for human diseases. The agreement includes up to $22.0 million in development and regulatory milestones, with a $1.5 million fee already paid for development candidate nomination and a $2.5 million milestone due upon first patient dosing in a Phase 1 trial. Jade will also pay low to mid-single-digit royalties on net sales.

Partner: Paragon Therapeutics, Inc.

Biogen Inc. anticipates pre-tax expenses of approximately $164 million in Q2 2026 and $290 million to $320 million in Q3 2026, impacting GAAP and non-GAAP EPS by $0.95 and $1.75-$1.95, respectively. These charges are related to acquired in-process research and development, including upfront and milestone payments from collaboration and license agreements. The Q3 figures are preliminary and pertain to potential transactions that have not yet closed.

REGENXBIO Inc. announced it has earned a $100.0 million milestone payment from AbbVie Global Enterprises Ltd., a subsidiary of AbbVie Inc. This payment was triggered by the dosing of the first patient in a Phase IIb/III clinical trial for investigational surabgene lomparvovec (sura-vec, ABBV-RGX-314) for diabetic retinopathy. The payment is expected to be received in July 2026, pursuant to their existing Collaboration and License Agreement.

Drug: surabgene lomparvovec (sura-vec, ABBV-RGX-314) · Indication: diabetic retinopathy · Partner: AbbVie Global Enterprises Ltd.

Zymeworks Inc. entered into a definitive merger agreement to acquire Theravance Biopharma, Inc. for $17.00 in cash per share plus one contingent value right (CVR) per share. The CVRs entitle holders to a pro rata share of 80% of net proceeds from any license or divestiture of ampreloxetine, a $50 million milestone payment upon its first commercial sale in specified territories, and 10% of net sales. The merger is expected to close in the second half of 2026, subject to customary closing conditions.

Drug: ampreloxetine · Partner: Theravance Biopharma, Inc.

Neurogene Inc. entered into an underwriting agreement for a public offering of common stock and pre-funded warrants. The offering, including the full exercise of the underwriters' option, is expected to generate net proceeds of approximately $134.8 million. The company anticipates these funds, combined with existing cash, will be sufficient to cover operating expenses and capital expenditures into the first quarter of 2029.

Pyxis Oncology, Inc. entered into a private placement agreement to issue common stock and warrants to institutional investors, raising approximately $50.0 million in gross proceeds. This financing is anticipated to extend the company's cash runway into the second quarter of 2027 and will support the continued advancement of its lead clinical program, micvotabart pelidotin (MICVO), through key clinical milestones.

MetaVia Inc. entered into an At The Market Offering Agreement with Ladenburg Thalmann & Co. Inc. to sell up to $4,000,000 of its common stock. This ATM offering allows the company to sell shares from time to time through or to Ladenburg.

BridgeBio Pharma, Inc. entered into an Investment Agreement to issue and sell Series A Cumulative Convertible Participating Preferred Stock to purchasers including Chinotto Investments, LLC and HCRx Investments HoldCo, L.P. The aggregate purchase price for 933,900 shares was $933.9 million. The Preferred Stock is convertible into common stock, ranks senior to common stock for dividends and liquidation, and includes provisions for dividend rates, conversion rights, and redemption options.

Enanta Pharmaceuticals, Inc. entered into an Open Market Sale Agreement with Jefferies LLC on July 2, 2026, establishing an at-the-market (ATM) offering program. This agreement allows the company to sell up to $75 million of its common stock through Jefferies LLC. Enanta will pay Jefferies a commission of up to 3.0% of the gross sales price for shares sold.